Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Antiplatelet therapy is extensively used in the primary and secondary prophylaxis of arterial thrombotic disorders. Aspirin, the most commonly used antiplatelet agent, is a cyclooxygenase−1 inhibitor and considered a mild to moderate inhibitor of platelet function. Therefore, often a second antiplatelet agent is necessary in certain clinical conditions requiring greater inhibition of platelet function. An adenosine diphosphate (ADP) receptor, P2Y12, is an important target for this purpose; several agents inhibit this receptor providing potent antiplatelet effect. One of the side effects of these agents is bleeding, which in some patients may require reversal of antiplatelet effect. Similarly, patients undergoing emergent surgeries may benefit from reversal of antiplatelet effect to avoid excessive surgical bleeding. This article reviews current literature on this topic.

Original languageEnglish (US)
JournalTransfusion Medicine Reviews
DOIs
StatePublished - Jan 1 2019

Fingerprint

Platelet Transfusion
Platelet Aggregation Inhibitors
Platelets
Blood Platelets
Hemorrhage
Purinergic P1 Receptors
Adenosine Diphosphate
Surgery
Aspirin
Therapeutics

Keywords

  • Antiplatelet therapy
  • Aspirin
  • P2Y12 inhibitors
  • Platelet transfusion

ASJC Scopus subject areas

  • Hematology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

@article{9ff6535096af441090ffd18ce1e34ea2,
title = "Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy",
abstract = "Antiplatelet therapy is extensively used in the primary and secondary prophylaxis of arterial thrombotic disorders. Aspirin, the most commonly used antiplatelet agent, is a cyclooxygenase−1 inhibitor and considered a mild to moderate inhibitor of platelet function. Therefore, often a second antiplatelet agent is necessary in certain clinical conditions requiring greater inhibition of platelet function. An adenosine diphosphate (ADP) receptor, P2Y12, is an important target for this purpose; several agents inhibit this receptor providing potent antiplatelet effect. One of the side effects of these agents is bleeding, which in some patients may require reversal of antiplatelet effect. Similarly, patients undergoing emergent surgeries may benefit from reversal of antiplatelet effect to avoid excessive surgical bleeding. This article reviews current literature on this topic.",
keywords = "Antiplatelet therapy, Aspirin, P2Y12 inhibitors, Platelet transfusion",
author = "Srikanth Nagalla and Ravindra Sarode",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.tmrv.2019.01.002",
language = "English (US)",
journal = "Transfusion Medicine Reviews",
issn = "0887-7963",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy

AU - Nagalla, Srikanth

AU - Sarode, Ravindra

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Antiplatelet therapy is extensively used in the primary and secondary prophylaxis of arterial thrombotic disorders. Aspirin, the most commonly used antiplatelet agent, is a cyclooxygenase−1 inhibitor and considered a mild to moderate inhibitor of platelet function. Therefore, often a second antiplatelet agent is necessary in certain clinical conditions requiring greater inhibition of platelet function. An adenosine diphosphate (ADP) receptor, P2Y12, is an important target for this purpose; several agents inhibit this receptor providing potent antiplatelet effect. One of the side effects of these agents is bleeding, which in some patients may require reversal of antiplatelet effect. Similarly, patients undergoing emergent surgeries may benefit from reversal of antiplatelet effect to avoid excessive surgical bleeding. This article reviews current literature on this topic.

AB - Antiplatelet therapy is extensively used in the primary and secondary prophylaxis of arterial thrombotic disorders. Aspirin, the most commonly used antiplatelet agent, is a cyclooxygenase−1 inhibitor and considered a mild to moderate inhibitor of platelet function. Therefore, often a second antiplatelet agent is necessary in certain clinical conditions requiring greater inhibition of platelet function. An adenosine diphosphate (ADP) receptor, P2Y12, is an important target for this purpose; several agents inhibit this receptor providing potent antiplatelet effect. One of the side effects of these agents is bleeding, which in some patients may require reversal of antiplatelet effect. Similarly, patients undergoing emergent surgeries may benefit from reversal of antiplatelet effect to avoid excessive surgical bleeding. This article reviews current literature on this topic.

KW - Antiplatelet therapy

KW - Aspirin

KW - P2Y12 inhibitors

KW - Platelet transfusion

UR - http://www.scopus.com/inward/record.url?scp=85061855562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061855562&partnerID=8YFLogxK

U2 - 10.1016/j.tmrv.2019.01.002

DO - 10.1016/j.tmrv.2019.01.002

M3 - Review article

C2 - 30814031

AN - SCOPUS:85061855562

JO - Transfusion Medicine Reviews

JF - Transfusion Medicine Reviews

SN - 0887-7963

ER -